[HTML][HTML] Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
NI Paton, J Musaazi, C Kityo, S Walimbwa… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
Integrase inhibitors: after 10 years of experience, is the best yet to come?
The era of the integrase strand transfer inhibitors (INSTI s) for the treatment of human
immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time …
immunodeficiency virus (HIV) infection began with raltegravir in 2007. Since that time …
Roadmap for achieving universal antiretroviral treatment
S Sokhela, S Lalla-Edward, MJ Siedner… - Annual review of …, 2023 - annualreviews.org
Modern antiretroviral therapy safely, potently, and durably suppresses human
immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired …
immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired …
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
Objective: Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would
provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir …
provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir …
Pretreatment and acquired antiretroviral drug resistance among persons living with HIV in four African countries
TA Crowell, B Danboise, A Parikh… - Clinical Infectious …, 2021 - academic.oup.com
Background Emerging HIV drug resistance (HIVDR) could jeopardize the success of
standardized HIV management protocols in resource-limited settings. We characterized …
standardized HIV management protocols in resource-limited settings. We characterized …
Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
Background Dolutegravir concentrations are reduced by efavirenz induction effect
necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction …
necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction …
Resistance testing for management of HIV virologic failure in sub-Saharan Africa: an unblinded randomized controlled trial
MJ Siedner, MYS Moosa, S McCluskey… - Annals of internal …, 2021 - acpjournals.org
Background: Virologic failure in HIV predicts the development of drug resistance and
mortality. Genotypic resistance testing (GRT), which is the standard of care after virologic …
mortality. Genotypic resistance testing (GRT), which is the standard of care after virologic …
[HTML][HTML] Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis
A Hauser, F Goldstein, ML Reichmuth… - Journal of clinical …, 2022 - Elsevier
Objective: To estimate the prevalence of NRTI and NNRTI drug resistance mutations in
patients failing NNRTI-based ART in Southern Africa. Study design: We conducted a …
patients failing NNRTI-based ART in Southern Africa. Study design: We conducted a …
Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource …
JA Brown, A Amstutz, BL Nsakala… - Journal of …, 2021 - academic.oup.com
Objectives WHO guidelines on ART define the HIV-1 viral load (VL) threshold for treatment
failure at 1000 copies/mL. The Switch Either near Suppression Or THOusand (SESOTHO) …
failure at 1000 copies/mL. The Switch Either near Suppression Or THOusand (SESOTHO) …
The management of treatment-experienced HIV patients (including virologic failure and switches)
J Cutrell, T Jodlowski, R Bedimo - Therapeutic advances in …, 2020 - journals.sagepub.com
Significant advances in the potency and tolerability of antiretroviral therapy (ART) have led
to very high rates of virologic success for most who remain adherent to therapy. As a result …
to very high rates of virologic success for most who remain adherent to therapy. As a result …